Evidence map›Paper›PMID 38727371›Full record

ArticleNanomaterials (Basel, Switzerland)2024

Modulation of the Effect of Cisplatin on Nicotine-Stimulated A549 Lung Cancer Cells Using Analog of Marine Sponge Toxin Loaded in Gelatin Nanoparticles.

Ahmad Joukhan, Veno Kononenko, Marija Sollner Dolenc, Matej Hočevar, Tom Turk, Damjana Drobne

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ahmad JoukhanDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0009-0003-1910-1880
Veno KononenkoDepartment of Biology, Faculty of Biotechnical, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0003-3066-0328
Marija Sollner DolencDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0002-0560-3762
Matej HočevarInstitute of Metals and Technology, 1000 Ljubljana, Slovenia.
Tom TurkDepartment of Biology, Faculty of Biotechnical, University of Ljubljana, 1000 Ljubljana, Slovenia.
Damjana DrobneDepartment of Biology, Faculty of Biotechnical, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0002-5970-7460

Funding

SLOVENIAN RESEARCH AND INNOVATION AGENCY J2-3052SLOVENIAN RESEARCH AND INNOVATION AGENCY J3-2520SLOVENIAN RESEARCH AND INNOVATION AGENCY J4-4550SLOVENIAN RESEARCH AND INNOVATION AGENCY P1-0207SLOVENIAN RESEARCH AND INNOVATION AGENCY P2-0424SLOVENIAN RESEARCH AND INNOVATION AGENCY Z1-2634
6 · The paper itself

Abstract

Nicotine activates nicotinic acetylcholine receptors (nAChRs), which are overexpressed in numerous cancer types, leading to signaling pathways that increase lung cancer invasiveness and resistance to chemotherapeutic agents. In this study, the effects of APS12-2, a synthetic analog of marine sponge toxin that acts as an antagonist of nAChRs, was investigated in vitro on A549 human lung adenocarcinoma cells and non-tumorigenic human lung epithelial BEAS-2B cells. In addition, gelatin nanoparticles (GNPs) loaded with APS12-2 (APS12-2-GNPs) were prepared and their effects were compared with those of free APS12-2. Nicotine reduced cytotoxicity, the formation of reactive oxygen species, and the formation of lipid droplets caused by cisplatin on A549 cells. The effects of nicotine on the decreased efficacy of cisplatin were reduced by APS12-2 and APS12-2-GNPs. APS12-2-GNPs showed a substantial advantage compared with free APS12-2; the cytotoxicity of APS12-2 on BEAS-2B cells was greatly reduced when APS12-2 was loaded in GNPs, whereas the cytotoxicity on A549 cells was only slightly reduced. Our results suggest that both APS12-2 and APS12-2-GNPs hold promise as supportive agents in the cisplatin-based chemotherapy of lung cancer.

Indexed as

APS12-2chemotherapeutic agentmarine toxinnAChRnAChR antagonist

Identifiers

PMID38727371
PMCPMC11085658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.